RTP Mobile Logo
CNS Tumor Board — Clinical Investigators Provide Perspectives on Current Cases from Their Practices
Released February 2013

Proceedings from a satellite symposium during the 17th annual meeting of the Society for Neuro-Oncology. Including perspectives from Drs Minesh P Mehta, Timothy F Cloughesy, Marc Chamberlain, Jon D Weingart and Tracy Batchelor. (Video Program)

CE Disclosures and Faculty Information


    This activity is intended for neuro-oncologists, neurosurgeons and other neuro-oncology specialists involved in the treatment of primary and metastatic central nervous system (CNS) cancers.


    Brain tumors are a diverse group of neoplasms arising from different cells within the CNS or from systemic tumors that have metastasized to the CNS. Primary brain tumors include a number of histologic types with markedly different tumor growth rates and are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) and glioblastoma multiforme (GBM) based on their histopathologic features. Despite treatment, the median survival for anaplastic oligodendroglioma is 2 to 3 years, and patients with GBM can succumb to their disease within a year of the onset. Thus, clinical education regarding standard and evolving best-practice therapeutic management of these neoplasms is essential to improving patient outcomes. To bridge the gap between research and patient care, these proceedings from a case-based CME symposium during the 17th annual meeting of the Society for Neuro-Oncology use the perspectives of leading neuro-oncologists and neurosurgeons to apply evidence-based concepts to routine practice. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.

    • Ensure delivery of appropriate treatment for primary brain cancer through facilitation of a multidisciplinary care plan.
    • Use clinical and molecular markers to assess disease prognosis and guide treatment selection, when appropriate, for patients with high-grade gliomas.
    • Apply the results of clinical research to the evidence-based use of chemotherapy and adjuvant chemoradiation therapy for patients with gliomas.
    • Communicate the benefits and risks of bevacizumab with chemotherapy to patients with newly diagnosed or recurrent GBM.
    • Recognize techniques to distinguish true disease progression from radiologic pseudoprogression among patients with treated brain tumors.
    • Describe the scientific rationale and recent research results that support ongoing investigation of novel treatments for patients with brain cancer.
    • Evaluate the current treatment algorithms for low-grade gliomas and CNS lymphoma and their impact on long-term patient outcomes.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity consists of a video component. To receive credit, the participant should watch the video.
    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Minesh P Mehta, MD
    Professor of Radiation Oncology
    Northwestern University
    Chicago, Illinois

    Board of Directors: Pharmacyclics Inc; Consulting Agreements: Abbott Laboratories, Bristol-Myers Squibb Company, Elekta, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Novocure, Schering-Plough Corporation, TomoTherapy, Verrex Corporation, ViewRay Incorporated; Data and Safety Monitoring Board: Apogenix GmbH; Medical Advisory Board: Adnexus, Colby Pharmaceutical Company, ProCertus BioPharm Inc, Stemina Biomarker Discovery Inc; Protocol Data Review: Adnexus; Stock Ownership: Accuray, Colby Pharmaceutical Company, Pharmacyclics Inc, ProCertus BioPharm Inc, Stemina Biomarker Discovery Inc.

    Timothy F Cloughesy, MD
    Director, Neuro-Oncology Program
    Director, Henry Singleton Brain Cancer Research Program
    Department of Neurology
    David Geffen School of Medicine at UCLA
    Los Angeles, California

    Advisory Committee: Celgene Corporation, EMD Serono Inc, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Genentech BioOncology, Millennium: The Takeda Oncology Company, Roche Laboratories Inc.

    Marc Chamberlain, MD
    University of Washington
    Department of Neurology and Neurological Surgery
    Chief, Division of Neuro-Oncology
    Fred Hutchinson Cancer Research Center
    Seattle Cancer Care Alliance
    Seattle, Washington

    Advisory Committee and Speakers Bureau: Genentech BioOncology.

    Jon D Weingart, MD
    Professor of Neurosurgery and Oncology
    Director, Neurosurgical Operating Room
    Johns Hopkins School of Medicine
    Baltimore, Maryland

    No real or apparent conflicts of interest to disclose.

    Tracy Batchelor, MD, MPH
    Executive Director
    Stephen E and Catherine Pappas Center for Neuro-Oncology
    Professor of Neurology
    Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Advisory Committee: Genentech BioOncology, Kyowa Hakko Kirin Co Ltd; Consulting Agreements: Advance Medical - Health Care Management Services, Champions Oncology Inc, Schering-Plough Corporation; Contracted Research: AstraZeneca Pharmaceuticals LP, Millennium: The Takeda Oncology Company, Pfizer Inc; Other Remunerated Activities: Oakstone Publishing LLC, UpToDate Inc; Speakers Bureau: RMEI LLC.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genentech BioOncology.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

    Last review date: February 2013
    Expiration date
    : February 2014

Acknowledge and close

Watch video
(WiFi is recommended for best performance):

Introduction: Dr Love
Module 1 –
Dr Mehta:
Management of Primary GBM
Module 2 –
Dr Cloughesy:
Novel/Anti-angiogenic Agents in GBM
Module 3 –
Dr Chamberlain:
Bevacizumab in Relapsed GBM
Module 4 –
Dr Weingart:
Astrocytoma, Low-Grade Gliomas
Module 5 –
Dr Batchelor:
CNS Lymphoma